FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150656793> ?p ?o ?g. }

• W2150656793 endingPage "82" @default.
• W2150656793 startingPage "60" @default.
• W2150656793 abstract "To describe the efficacy and safety of vortioxetine for the treatment of major depressive disorder (MDD).The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/, http://www.clinicaltrialsregister.eu and http://www.clinicaltrials.gov for the search terms 'vortioxetine' and 'Lu AA21004', and by obtaining posters presented at congresses. Product labelling provided additional information.All available clinical reports of studies were identified.Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information.Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. The recommended dose range is 5-20 mg/day. Approval for the treatment of MDD was based on a clinical development programme that included six positive 6-8 week studies, including one study in elderly people, and one positive maintenance study in adults. In the informative short-term studies in non-elderly patients, NNT for response with vortioxetine vs. placebo was 7 (95% CI 6-9), and NNT for remission vs. placebo was 11 (95% CI 8-17). NNH for discontinuation because of an adverse event (AE) was 36 (95% CI 24-70). The most commonly encountered AEs (incidence ≥ 5% and at least twice the rate of placebo) as identified in product labelling were nausea, constipation and vomiting, with NNH values vs. placebo of 6 (95% CI 6-7), 64 (95% CI 37-240), and 28 (95% CI 23-38), respectively. Changes in weight were not clinically relevant.Vortioxetine represents another option for the treatment of MDD. Vortioxetine appears to have a favourable weight-gain profile. Additional information regarding the time course of response/remission and for the commonly occurring AE of nausea would be helpful to better characterise this agent. Pending clinical trials include those examining cognitive dysfunction that can accompany MDD." @default.
• W2150656793 created "2016-06-24" @default.
• W2150656793 creator A5013970045 @default.
• W2150656793 date "2013-10-25" @default.
• W2150656793 modified "2023-09-23" @default.
• W2150656793 title "Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?" @default.
• W2150656793 cites W1570504112 @default.
• W2150656793 cites W1968692357 @default.
• W2150656793 cites W1969328451 @default.
• W2150656793 cites W1970755410 @default.
• W2150656793 cites W1976410377 @default.
• W2150656793 cites W1980544360 @default.
• W2150656793 cites W1983215890 @default.
• W2150656793 cites W1987514922 @default.
• W2150656793 cites W1987560991 @default.
• W2150656793 cites W1988309578 @default.
• W2150656793 cites W1998023765 @default.
• W2150656793 cites W2008641178 @default.
• W2150656793 cites W2011606125 @default.
• W2150656793 cites W2012424074 @default.
• W2150656793 cites W2013402663 @default.
• W2150656793 cites W2029290656 @default.
• W2150656793 cites W2029732660 @default.
• W2150656793 cites W2030270520 @default.
• W2150656793 cites W2034459370 @default.
• W2150656793 cites W2034900982 @default.
• W2150656793 cites W2036812642 @default.
• W2150656793 cites W2043310433 @default.
• W2150656793 cites W2048026164 @default.
• W2150656793 cites W2054766240 @default.
• W2150656793 cites W2055651890 @default.
• W2150656793 cites W2059274457 @default.
• W2150656793 cites W2061669920 @default.
• W2150656793 cites W2066283885 @default.
• W2150656793 cites W2069176680 @default.
• W2150656793 cites W2084170778 @default.
• W2150656793 cites W2094916253 @default.
• W2150656793 cites W2102298517 @default.
• W2150656793 cites W2157463034 @default.
• W2150656793 cites W3154170385 @default.
• W2150656793 cites W4235467202 @default.
• W2150656793 doi "https://doi.org/10.1111/ijcp.12350" @default.
• W2150656793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24165478" @default.
• W2150656793 hasPublicationYear "2013" @default.
• W2150656793 type Work @default.
• W2150656793 sameAs 2150656793 @default.
• W2150656793 citedByCount "90" @default.
• W2150656793 countsByYear W21506567932013 @default.
• W2150656793 countsByYear W21506567932014 @default.
• W2150656793 countsByYear W21506567932015 @default.
• W2150656793 countsByYear W21506567932016 @default.
• W2150656793 countsByYear W21506567932017 @default.
• W2150656793 countsByYear W21506567932018 @default.
• W2150656793 countsByYear W21506567932019 @default.
• W2150656793 countsByYear W21506567932020 @default.
• W2150656793 countsByYear W21506567932021 @default.
• W2150656793 countsByYear W21506567932022 @default.
• W2150656793 countsByYear W21506567932023 @default.
• W2150656793 crossrefType "journal-article" @default.
• W2150656793 hasAuthorship W2150656793A5013970045 @default.
• W2150656793 hasConcept C118552586 @default.
• W2150656793 hasConcept C126322002 @default.
• W2150656793 hasConcept C142454548 @default.
• W2150656793 hasConcept C142724271 @default.
• W2150656793 hasConcept C170493617 @default.
• W2150656793 hasConcept C197934379 @default.
• W2150656793 hasConcept C204787440 @default.
• W2150656793 hasConcept C27081682 @default.
• W2150656793 hasConcept C2778034309 @default.
• W2150656793 hasConcept C2778715236 @default.
• W2150656793 hasConcept C2778938600 @default.
• W2150656793 hasConcept C2779177272 @default.
• W2150656793 hasConcept C2780051608 @default.
• W2150656793 hasConcept C2780580376 @default.
• W2150656793 hasConcept C2780733359 @default.
• W2150656793 hasConcept C558461103 @default.
• W2150656793 hasConcept C58732023 @default.
• W2150656793 hasConcept C67774102 @default.
• W2150656793 hasConcept C71924100 @default.
• W2150656793 hasConcept C98274493 @default.
• W2150656793 hasConceptScore W2150656793C118552586 @default.
• W2150656793 hasConceptScore W2150656793C126322002 @default.
• W2150656793 hasConceptScore W2150656793C142454548 @default.
• W2150656793 hasConceptScore W2150656793C142724271 @default.
• W2150656793 hasConceptScore W2150656793C170493617 @default.
• W2150656793 hasConceptScore W2150656793C197934379 @default.
• W2150656793 hasConceptScore W2150656793C204787440 @default.
• W2150656793 hasConceptScore W2150656793C27081682 @default.
• W2150656793 hasConceptScore W2150656793C2778034309 @default.
• W2150656793 hasConceptScore W2150656793C2778715236 @default.
• W2150656793 hasConceptScore W2150656793C2778938600 @default.
• W2150656793 hasConceptScore W2150656793C2779177272 @default.
• W2150656793 hasConceptScore W2150656793C2780051608 @default.
• W2150656793 hasConceptScore W2150656793C2780580376 @default.
• W2150656793 hasConceptScore W2150656793C2780733359 @default.
• W2150656793 hasConceptScore W2150656793C558461103 @default.
• W2150656793 hasConceptScore W2150656793C58732023 @default.
• W2150656793 hasConceptScore W2150656793C67774102 @default.

• next